Impact of Cannabis Use on Long-Term Remission in Bipolar I and Schizoaffective Disorder
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectiveaaTo investigate the impact of regular cannabis use on long-term remission of mood symptoms in bipolar spectrum disorders. MethodsaaThe 24-month prospective observational study included patients (n=239) with bipolar I disorder and schizoaffective disorder, bipolar type. Participants were classified as regular cannabis users (three times or more per week) or non-users. The primary outcome measure was the achievement of remission on the evaluations during the 24 months. ResultsaaOf the 234 participants for whom data was available, 25 (10.7%) were regular cannabis users, and the group comprised significantly more males than females. In the total population, cannabis use was significantly associated with decreased likelihood of remission during the 24-month follow-up period. Subgroup analyses showed that cannabis use was significantly associated with lower remission rates on the Hamilton Depression Rating Scale in females (n=139) and patients prescribed mood stabilizers alone (n=151), whereas in males (n=95) and patients prescribed olanzapine and/or a mood stabilizer (n=83), cannabis use was significantly associated with lower remission rates on the Young Mania Rating Scale. Remission rates were lowest in the concurrent cannabis and tobacco smoking group (n=22) followed by the tobacco smoking only group (n=97), and the non-smoker group (n=116). The post-hoc analysis revealed that all remission rates were significantly lower in the concurrent cannabis and the tobacco smoking group compared to the non-smoker group. ConclusionaaCannabis use negatively affects the long-term clinical outcome in patients with bipolar spectrum disorders. A comprehensive assessment and integrated management of cannabis use are required to achieve better treatment outcomes for bipolar spectrum disorders.
Abstract
ObjectiveaaTo investigate the impact of regular cannabis use on long-term remission of mood symptoms in bipolar spectrum disorders. MethodsaaThe 24-month prospective observational study included patients (n=239) with bipolar I disorder and schizoaffective disorder, bipolar type. Participants were classified as regular cannabis users (three times or more per week) or non-users. The primary outcome measure was the achievement of remission on the evaluations during the 24 months. ResultsaaOf the 234 participants for whom data was available, 25 (10.7%) were regular cannabis users, and the group comprised significantly more males than females. In the total population, cannabis use was significantly associated with decreased likelihood of remission during the 24-month follow-up period. Subgroup analyses showed that cannabis use was significantly associated with lower remission rates on the Hamilton Depression Rating Scale in females (n=139) and patients prescribed mood stabilizers alone (n=151), whereas in males (n=95) and patients prescribed olanzapine and/or a mood stabilizer (n=83), cannabis use was significantly associated with lower remission rates on the Young Mania Rating Scale. Remission rates were lowest in the concurrent cannabis and tobacco smoking group (n=22) followed by the tobacco smoking only group (n=97), and the non-smoker group (n=116). The post-hoc analysis revealed that all remission rates were significantly lower in the concurrent cannabis and the tobacco smoking group compared to the non-smoker group. ConclusionaaCannabis use negatively affects the long-term clinical outcome in patients with bipolar spectrum disorders. A comprehensive assessment and integrated management of cannabis use are required to achieve better treatment outcomes for bipolar spectrum disorders.
참고문헌 (55)
- Saddichha S, "How is substance use linked to psychosis? A study of the course and patterns of substance dependence in psychosis", Subst Abus, 31, pp.58~67 (2010)
- Lev-Ran S, "Bipolar disorder and co-occurring cannabis use disorders: characteristics, co-morbidities and clinical correlates", Psychiatry Res, 209, pp.459~465 (2013)
- Linszen DH, "Cannabis abuse and the course of recent-onset schizophrenic disorders", Arch Gen Psychiatry, 51, pp.273~279 (1994)
- Caspari D, "Cannabis and schizophrenia: results of a follow-up study", Eur Arch Psychiatry Clin Neurosci, 249, pp.45~49 (1999)
- Grech A, "Cannabis use and outcome of recent onset psychosis", Eur Psychiatry, 20, pp.349~353 (2005)
- De Hert M, "Effects of cannabis use on age at onset in schizophrenia and bipolar disorder", Schizophr Res, 126, pp.270~276 (2011)
- Estroff TW, "Drug abuse and bipolar disorders", Intl J Psychiatry Med, 15, pp.37~40 (1985)
- Cassidy F, "Substance abuse in bipolar disorder", Bipolar Disord, 3, pp.181~188 (2001)
- Agrawal A, "Cannabis involvement in individuals with bipolar disorder", Psychiatry Res, 185, pp.459~461 (2011)
- Lagerberg TV, "Excessive cannabis use is associated with earlier age at onset in bipolar disorder", Eur Arch Psychiatry Clin Neurosci, 261, pp.397~405 (2011)
- Lagerberg TV, "Indications of a dose-response relationship between cannabis use and age at onset in bipolar disorder", Psychiatry Res, 215, pp.101~104 (2014)
- Aas M, "Additive effects of childhood abuse and cannabis abuse on clinical expressions of bipolar disorders", Psychol Med, 44, pp.1653~1662 (2014)
- Strakowski SM, "The impact of substance abuse on the course of bipolar disorder", Biol Psychiatry, 48, pp.477~485 (2000)
- Baethge C, "Substance abuse in first-episode bipolar I disorder: indications for early intervention", Am J Psychiatry, 162, pp.1008~1010 (2005)
- van Rossum I, "Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis", J Nerv Ment Dis, 197, pp.35~40 (2009)
- Strakowski SM, "Effects of co-occurring alcohol abuse on the course of bipolar disorder following a first hospitalization for mania", Arch Gen Psychiatry, 62, pp.851~858 (2005)
- Berk M, "Going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania", J Affect Disord, 110, pp.126~134 (2008)
- Dodd S, "A prospective study of the impact of smoking on outcomes in bipolar and schizoaffective disorder", Compr Psychiatry, 51, pp.504~509 (2010)
- Bakare MO, "Co-morbid disorders and sexual risk behavior in Nigerian adolescents with bipolar disorder", Int Arch Med, 2, pp.16~ (2009)
- Cotton SM, "Gender differences in first episode psychotic mania", BMC Psychiatry, 13, pp.82~ (2013)
- Farren CK, "Gender differences in outcome at 2-year follow-up of treated bipolar and depressed alcoholics", J Stud Alcohol Drugs, 72, pp.872~880 (2011)
- Nivoli AM, "Gender differences in a cohort study of 604 bipolar patients: the role of predominant polarity", J Affect Disord, 133, pp.443~449 (2011)
- Kulkarni J, "The Bipolar Comprehensive Outcomes Study (BCOS): baseline findings of an Australian cohort study", J Affect Disord, 107, pp.135~144 (2008)
- Berk M, "History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder", J Affect Disord, 103, pp.181~186 (2007)
- Sheehan DV, "The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10", J Clin Psychiatry, 59(Suppl 20), pp.22~33 (1998)
- Young RC, "A rating scale for mania: reliability, validity and sensitivity", Br J Psychiatry, 133, pp.429~435 (1978)
- Lam RW, "Assessment Scales in Depression, Mania and Anxiety" (2005), Taylor and Francis
- Hamilton M, "A rating scale for depression", J Neurol Neurosurg Psychiatry, 23, pp.56~62 (1960)
- Tohen M, "The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders", Bipolar Disord, 11, pp.453~473 (2009)
- Kulkarni J, "Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice", BMC Psychiatry, 12, pp.228~ (2012)
- Guy W, "ECDEU Assessment Manual for Psychopharmacology" (1976), U.S. National Institute of Health, Psychopharmacology Research Branch
- Heffner JL, "Cigarette smoking in the early course of bipolar disorder : association with ages-at-onset of alcohol and marijuana use", Bipolar Disord, 10, pp.838~845 (2008)
- Macgregor S, "Cannabis Use and Mental Health: Findings from a Sample of Offenders in Police Custody. Criminal Justice Bulletin 9" (2012), National Cannabis Prevention and Information Centre
- Henquet C, "Cannabis use and expression of mania in the general population", J Affect Disord, 95, pp.103~110 (2006)
- Strakowski SM, "Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania", Arch Gen Psychiatry, 64, pp.57~64 (2007)
- Patton GC, "Cannabis use and mental health in young people: cohort study", BMJ, 325, pp.1195~1198 (2002)
- Rey JM, "Cannabis and mental health", BMJ, 325, pp.1183~1184 (2002)
- Degenhardt L, "Exploring the association between cannabis use and depression", Addiction, 98, pp.1493~1504 (2003)
- Fergusson DM, "Early onset cannabis use and psychosocial adjustment in young adults", Addiction, 92, pp.279~296 (1997)
- Conus P, "Pretreatment and outcome correlates of past sexual and physical trauma in 118 bipolar I disorder patients with a first episode of psychotic mania", Bipolar Disord, 12, pp.244~252 (2010)
- Kim SW, "Impact of childhood adversity on the course and suicidality of depressive disorders: the CRESCEND study", Depress Anxiety, 30, pp.965~974 (2013)
- Stange JP, "Extreme attributions predict the course of bipolar depression: results from the STEP-BD randomized controlled trial of psychosocial treatment", J Clin Psychiatry, 74, pp.249~255 (2013)
- Stange JP, "Extreme attributions predict suicidal ideation and suicide attempts in bipolar disorder: prospective data from STEP-BD", World Psychiatry, 13, pp.95~96 (2014)
- Kosel BW, "The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir", AIDS, 16, pp.543~550 (2002)
- Stout SM, "Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review", Drug Metab Rev, 46, pp.86~95 (2014)
- Chetty M, "Smoking and body weight influence the clearance of chlorpromazine", Eur J Clin Pharmacol, 46, pp.523~526 (1994)
- Kroon LA, "Drug interactions with smoking", Am J Health Syst Pharm, 64, pp.1917~1921 (2007)
- Strakowski SM, "Twelve-month outcome after a first hospitalization for affective psychosis", Arch Gen Psychiatry, 55, pp.49~55 (1998)
- Berk L, "Enhancing medication adherence in patients with bipolar disorder", Hum Psychopharmacol, 25, pp.1~16 (2010)
- González-Pinto A, "Assessment of medication adherence in a cohort of patients with bipolar disorder", Pharmacopsychiatry, 43, pp.263~270 (2010)
- de Leon J, "Variables associated with alcohol, drug, and daily smoking cessation in patients with severe mental illness", J Clin Psychiatry, 66, pp.1447~1455 (2005)
- Heffner JL, "Cigarette smoking and its relationship to mood disorder symptoms and co-occurring alcohol and cannabis use disorders following first hospitalization for bipolar disorder", Bipolar Disord, 14, pp.99~108 (2012)
- Peters EN, "Psychiatric, psychosocial, and physical health correlates of co-occurring cannabis use disorders and nicotine dependence", Drug Alcohol Depend, 134, pp.228~234 (2014)
- Waxmonsky JA, "Prevalence and correlates of tobacco use in bipolar disorder: data from the first 2000 participants in the Systematic Treatment Enhancement Program", Gen Hosp Psychiatry, 27, pp.321~328 (2005)
- Levin FR, "Bipolar disorder and substance abuse", Biol Psychiatry, 56, pp.738~748 (2004)